Zorevunersen sodium is an antisense oligonucleotide commercialized by Stoke Therapeutics, with a leading Phase II program in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy). According to Globaldata, it is involved in 6 clinical trials, of which 1 was completed, 4 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Zorevunersen sodium’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Zorevunersen sodium is expected to reach an annual total of $107 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Zorevunersen sodium Overview
Zorevunersen sodium (STK-001) is under development for the treatment of Dravet syndrome. It is administered via intrathecal route. It is developed based on targeted augmentation of nuclear gene output (TANGO) technology, RNA splicing. The therapeutic candidate increases productive SCN1 mRNA and consequently restore levels of Nav1.1 protein.
Stoke Therapeutics Overview
Stoke Therapeutics is a biotechnology company that develops antisense oligonucleotide which targets RNA splicing to enhance gene expression for the treatment of genetic diseases. The company is developing programs that are in preclinical development for eye and dravet syndrome and central nervous system conditions. Stoke Therapeutics harnesses targeted augmentation of nuclear gene output (TANGO) technology to develop its product portfolio. The company’s pipeline products address the diseases of dgavet syndrome and autosomal dominant optic atrophy. Stoke Therapeutics is headquartered in Bedford, Massachusetts, the US.
The company reported revenues of (US Dollars) US$12.4 million for the fiscal year ended December 2022 (FY2022). The operating loss of the company was US$104.4 million in FY2022, compared to an operating loss of US$86.1 million in FY2021. The net loss of the company was US$101.1 million in FY2022, compared to a net loss of US$85.8 million in FY2021.
For a complete picture of Zorevunersen sodium’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
